PTAB challenges

Proceedings overview

A single AIA trial proceeding, IPR2025-01125, has been filed against US patent 12089889. This proceeding resulted in a discretionary denial, meaning the Patent Trial and Appeal Board (PTAB) declined to institute a trial. As a result, no claims of US12089889 were invalidated or sustained by the PTAB. This outcome gives a defendant a stronger defensive posture regarding IPR challenges to this specific patent, as the patent has survived a petition for inter partes review, albeit through a discretionary denial rather than a decision on the merits.

IPR2025-01125 — Aerin Medical Inc. v. Neurent Medical Ltd.

• Type: Inter Partes Review
• Filed: 2025-06-24
• Status: Discretionary Denial. This means the PTAB, exercising its discretion, decided not to institute an inter partes review trial, rather than making a decision on the patentability of the challenged claims on their merits.
• Judge panel: The specific judge panel for this discretionary denial is not publicly available in the provided information or search results for this case number. Typically, discretionary denials are often made by the Director of the USPTO, possibly in consultation with PTAB judges, especially under the interim processes for workload management that were in place around the time of this decision.
• Petition grounds: Specific details regarding the claims challenged, prior art relied upon, and statutory basis (§ 102 / § 103 / § 112) for IPR2025-01125 on US12089889 were not found in the provided structured data or search results. However, related IPRs filed by Aerin Medical Inc. against Neurent Medical Ltd. around the same time challenged claims as obvious over prior art such as Townley (Application # 2016/0331459), which was the inventor's own prior work. It is plausible that similar grounds were raised against US12089889, potentially arguing obviousness of the claimed methods for improving nasal breathability or treating rhinosinusitis symptoms.
• Institution decision: Denied on 2025-12-23 (last modified date of the proceeding, often indicative of the decision date). The denial was discretionary. Discretionary denials often occur when there is parallel district court litigation, and the PTAB considers factors such as the timing of the district court trial relative to the expected Final Written Decision from the IPR, or inconsistent claim construction positions between the IPR and district court proceedings. Without the specific decision document for IPR2025-01125, the exact reasoning for this specific discretionary denial cannot be definitively stated.
• Final Written Decision: Not issued, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied.
• Appeal: Not applicable, as institution was denied. Decisions on institution, particularly discretionary denials, are generally barred from appellate review by 35 U.S.C. § 314(d).
• Defensive value: This discretionary denial means that the claims of US12089889 remain untested by the PTAB. For a defendant facing assertion of this patent, the patent owner can point to the denial as evidence that the patent has withstood a challenge. However, a discretionary denial does not affirm the patentability of the claims on their merits, and a defendant not in privity with Aerin Medical Inc. would not be estopped from filing their own IPR petition or raising the same or similar prior art in district court.

Strategic summary

Currently, all claims of US12089889 remain UNTESTED by the PTAB. Since the single IPR proceeding, IPR2025-01125, resulted in a discretionary denial, no claims were canceled or specifically found patentable by the Board. This means the patent owner's claims have not been narrowed by PTAB action.

The estoppel landscape for this patent is relatively clear: because institution was denied, the petitioner (Aerin Medical Inc.) and its privies are not subject to the statutory estoppel provisions of § 315(e)(2) for grounds that were raised or reasonably could have been raised in the petition. However, the Board's discretionary denial may have been based on factors related to parallel litigation or other policy considerations, rather than the merits of the patentability challenge. Therefore, a new defendant being asserted against, particularly one not in privity with Aerin Medical Inc., could theoretically challenge the same claims with the same or different prior art grounds, although they would need to be mindful of the reasons for the prior discretionary denial and how to avoid a similar outcome.

There is a signal of a pattern of IPRs filed by Aerin Medical Inc. against Neurent Medical Ltd.'s patents, as multiple IPRs (e.g., IPR2025-01126 and IPR2025-01127) were filed around the same time challenging related patents. This indicates active litigation between these parties and a strategic use of IPRs by Aerin. The discretionary denial here suggests that the PTAB, under its interim workload management processes, might have prioritized other considerations over a full merits review, potentially due to parallel district court litigation.

Recommended next steps

Given that IPR2025-01125 resulted in a discretionary denial and no claims of US12089889 were invalidated:

• No claims invalidated: There is no PTAB Final Written Decision to cite for invalidated claims. All claims of US12089889 remain intact from a PTAB perspective.
• Absence of active proceedings: Currently, there are no active PTAB proceedings on US12089889. The absence of further PTAB activity after a discretionary denial suggests that for now, the patent owner has successfully fended off an IPR challenge. However, this also means the patent's validity has not been fully adjudicated by the PTAB.
• Strategic Consideration: For a potential defendant, understanding the specific reasons for the discretionary denial in IPR2025-01125 would be crucial. If the denial was based on factors like the timing of parallel district court litigation (e.g., Fintiv factors), a new petitioner might be able to craft a petition that avoids these discretionary hurdles, especially if they are not involved in parallel litigation or can demonstrate a timeline that favors PTAB review.